(S) -N- (3- (6-Isopropoxypyridin-3-yl) -1H-indazol-5-yl) -1- (2- (4- (4- (1-methyl) for pharmaceutical preparations -1H-1,2,4-triazol-3-yl) phenyl) -3,6-dihydropyridin-1 (2H) -yl) -2-oxoethyl) -3- (methylthio) pyrrolidine-3-carboxamide composition

摘要

The present invention relates to an active ingredient (S) -N- (3- (6-isopropoxypyridin-3-yl) -1H-indazol-5-yl) -1- (2- (4- (4- (1- Methyl-1H-1,2,4-triazol-3-yl) phenyl) -3,6-dihydropyridin-1 (2H) -yl) -2-oxoethyl) -3- (methylthio) pyrrolidine-3-carboxamide The total amount of active ingredients, including the granular composition, is about 60-90% by weight of (S) -N- (3- (6-isopropoxypyridin-3-yl) -1H-indazol-5-yl) -1 -(2- (4- (4- (1-Methyl-1H-1,2,4-triazol-3-yl) phenyl) -3,6-dihydropyridin-1 (2H) -yl) -2-oxoethyl) -3- (Methylthio) pyrrolidine-3-carbox Mid-form 1HCl, about 10-30 wt% of (S) -N- (3- (6-isopropoxypyridin-3-yl) -1H-indazol-5-yl) -1- (2- (4- ( 4- (1-Methyl-1H-1,2,4-triazol-3-yl) phenyl) -3,6-dihydropyridin-1 (2H) -yl) -2-oxoethyl) -3- (methylthio) pyrrolidine- 3-carboxamide amorphous HCl, and about 0-5 wt% (S) -N- (3- (6-isopropoxypyridin-3-yl) -1H-indazol-5-yl) -1- (2 -(4- (4- (1-Methyl-1H-1,2,4-triazol-3-yl) phenyl) -3,6-dihydropyridin-1 (2H) -yl) -2-oxoethyl) -3- (Methylthio) pyrrolidine-3-carboxami Containing amorphous free base. [Selection] Figure 1